SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process

Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

Altasciences and Certara forge strategic pact to speed early drug development

Co-Diagnostics JV leases manufacturing facility in Saudi Arabia

CoMira Diagnostics will manufacture PCR diagnostic instruments and medical consumables in Sudair Industrial City

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit

Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial

NEJM study shows strong protection across strains